...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Microencapsulation: Microcapsules Liposomes Nanoparticles Microcells Microspheres >Non-small cell lung cancer tumour antigen, MUC-1 peptide-loaded non-aggregated poly (lactide-co-glycolide) nanoparticles augmented cellular uptake in mouse professional antigen-presenting cells: optimisation and characterisation
【24h】

Non-small cell lung cancer tumour antigen, MUC-1 peptide-loaded non-aggregated poly (lactide-co-glycolide) nanoparticles augmented cellular uptake in mouse professional antigen-presenting cells: optimisation and characterisation

机译：非小细胞肺癌肿瘤抗原，MUC-1肽负载的非聚集聚（丙交酯 - 共乙酰胺）纳米颗粒在小鼠专业抗原呈递细胞中增加了细胞摄取：优化和表征

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: MUC-1 lipopeptide vaccine exhibited immense potential in the treatment of non-small cell lung cancer (NSCLC) in both preclinical and clinical trials. However, it lacks triggering of mucosal immunity at the site of action. Therefore, in present investigation, MUC-1 peptide-loaded poly(lactide-co-glycolide) nanoparticles (MUC-1 peptide-PLGA-NPs) and MUC-1 peptide-loaded poly(lactide-co-glycolide) non-aggregated nanoparticles (MUC-1 peptide-PLGA-NA-NPs) using Central Composite Design (CCD) were customised. Methods and Results: The mean particle size of MUC-1 peptide PLGA-NPs was estimated to be 176.7 +/- 32.7 nm, significantly (p < 0.05) higher than 100.3 +/- 24.3 nm of MUC-1 peptide-PLGA-NA-NPs. Furthermore, integrity and stability of MUC-1 were maintained in MUC-1 peptide PLGA-NA-NPs. MUC-1 peptide-PLGA-NA-NPs exhibited augmented cellular uptake in mouse RAW264.7 macrophages preferably by clathrin-mediated endocytosis pathway as compared to phagocytosis followed by MUC-1-peptide PLGA-NPs owing to size <= 100 nm, and spherical shape. Conclusion: MUC-1 peptide-PLGA-NA-NPs may be a potential candidate to study antitumor potential in xenograft model of NSCLC through inhalation route of administration.
机译：目的：MUC-1脂肽疫苗在非小细胞肺癌（NSCLC）的临床前和临床试验中均显示出巨大的潜力。然而，它缺乏在作用部位触发粘膜免疫。因此，在本研究中，使用中心复合设计（CCD）定制了MUC-1肽负载聚（丙交酯-共-乙交酯）纳米粒（MUC-1肽-PLGA纳米粒）和MUC-1肽负载聚（丙交酯-共-乙交酯）非聚集纳米粒（MUC-1肽-PLGA纳米粒）。方法和结果：MUC-1肽PLGA纳米粒的平均粒径估计为176.7+/-32.7nm，显著高于MUC-1肽PLGA纳米粒的100.3+/-24.3nm（p<0.05）。此外，MUC-1肽PLGA-NA纳米粒保持了MUC-1的完整性和稳定性。在小鼠RAW264中，MUC-1肽PLGA-NA NPs显示出细胞摄取增强。7.巨噬细胞最好是通过网格蛋白介导的内吞途径，而不是吞噬后的MUC-1肽PLGA纳米粒，因为其大小小于等于100纳米，呈球形。结论：MUC-1肽PLGA-NA纳米粒可能是通过吸入给药途径研究NSCLC异种移植模型抗肿瘤潜能的潜在候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号